MYGN Valuation

Myriad Genetics Inc

Add to Watchlist

Advanced Chart

6.190

-0.13(-2.057%)1D

Overview
Forecast
Valuation
Earnings

MYGN Relative Valuation

MYGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MYGN is overvalued; if below, it's undervalued.

Historical Valuation

Myriad Genetics Inc (MYGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.70 is considered Undervalued compared with the five-year average of -32.21. The fair price of Myriad Genetics Inc (MYGN) is between 12.90 to 24.74 according to relative valuation methord. Compared to the current price of 6.21 USD , Myriad Genetics Inc is Undervalued By 51.87%.

Relative Value

Fair Zone

12.90-24.74

Current Price：6.21

51.87%

Undervalued

128.56

Trailing

Forward

21.28

EV/EBITDA

Myriad Genetics Inc. (MYGN) has a current EV/EBITDA of 21.28. The 5-year average EV/EBITDA is 37.69. The thresholds are as follows: Strongly Undervalued below -133.67, Undervalued between -133.67 and -47.99, Fairly Valued between 123.36 and -47.99, Overvalued between 123.36 and 209.04, and Strongly Overvalued above 209.04. The current Forward EV/EBITDA of 21.28 falls within the Historic Trend Line -Fairly Valued range.

61.52

EV/EBIT

Myriad Genetics Inc. (MYGN) has a current EV/EBIT of 61.52. The 5-year average EV/EBIT is -3738.30. The thresholds are as follows: Strongly Undervalued below -36747.83, Undervalued between -36747.83 and -20243.06, Fairly Valued between 12766.47 and -20243.06, Overvalued between 12766.47 and 29271.24, and Strongly Overvalued above 29271.24. The current Forward EV/EBIT of 61.52 falls within the Historic Trend Line -Fairly Valued range.

0.70

Myriad Genetics Inc. (MYGN) has a current PS of 0.70. The 5-year average PS is 2.34. The thresholds are as follows: Strongly Undervalued below 0.68, Undervalued between 0.68 and 1.51, Fairly Valued between 3.17 and 1.51, Overvalued between 3.17 and 4.00, and Strongly Overvalued above 4.00. The current Forward PS of 0.70 falls within the Undervalued range.

26.37

P/OCF

Myriad Genetics Inc. (MYGN) has a current P/OCF of 26.37. The 5-year average P/OCF is 38.83. The thresholds are as follows: Strongly Undervalued below -214.36, Undervalued between -214.36 and -87.76, Fairly Valued between 165.42 and -87.76, Overvalued between 165.42 and 292.01, and Strongly Overvalued above 292.01. The current Forward P/OCF of 26.37 falls within the Historic Trend Line -Fairly Valued range.

-345.91

P/FCF

Myriad Genetics Inc. (MYGN) has a current P/FCF of -345.91. The 5-year average P/FCF is 0.84. The thresholds are as follows: Strongly Undervalued below -333.40, Undervalued between -333.40 and -166.28, Fairly Valued between 167.96 and -166.28, Overvalued between 167.96 and 335.08, and Strongly Overvalued above 335.08. The current Forward P/FCF of -345.91 falls within the Strongly Undervalued range.

Myriad Genetics Inc (MYGN) has a current Price-to-Book (P/B) ratio of 1.52. Compared to its 3-year average P/B ratio of 2.03 , the current P/B ratio is approximately -25.39% higher. Relative to its 5-year average P/B ratio of 2.06, the current P/B ratio is about -26.54% higher. Myriad Genetics Inc (MYGN) has a Forward Free Cash Flow (FCF) yield of approximately -6.43%. Compared to its 3-year average FCF yield of -7.57%, the current FCF yield is approximately -15.11% lower. Relative to its 5-year average FCF yield of -5.18% , the current FCF yield is about 24.14% lower.

1.47

P/B

Median3y

2.03

Median5y

2.06

-6.43

FCF Yield

Median3y

-7.57

Median5y

-5.18

Competitors Valuation Multiple

The average P/S ratio for MYGN's competitors is 1.01, providing a benchmark for relative valuation. Myriad Genetics Inc Corp (MYGN) exhibits a P/S ratio of 0.70, which is -31.21% above the industry average. Given its robust revenue growth of 0.76%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Organogenesis Holdings Inc

Castle Biosciences Inc

Performance Decomposition

Market capitalization of MYGN decreased by 78.15% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -17.35 to -155.09.

The secondary factor is the Revenue Growth, contributed 0.76%to the performance.

Overall, the performance of MYGN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

0.76%

211.50M → 213.10M

Revenue Growth

793.89%

-17.35 → -155.09

Margin Expansion

-872.80%

0.18 → -1.42

P/E Change

-78.15%